Pharmacokinetic considerations for optimizing inhaled spray-dried pyrazinoic acid formulations
S. B. Yeshwante, P. Hanafin, B. Miller, L. Rank, S. Murcia, C. Xander, A. Annis, V. Baxter, E. Anderson, B. Jermain, R. Konicki, A. Schmalstig, I. Stewart, M. Braunstein, A. Hickey, G. G. Rao
This study develops and evaluates inhaled POA formulations to improve TB treatment by enhancing pulmonary exposure and efficacy against pncA-mutant Mtb.
bioRxiv · Apr 1, 2023Pharmacology & Toxicology